We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Macrophages from HIV Cancer Victims Are Carcinogenic

By Biotechdaily staff writers
Posted on 10 Oct 2002
A study has found that macrophages from HIV-infected lymphoma patients injected into severe combined immunodeficient (SCID) mice induced aggressive mouse T-cell lymphomas in the animals while macrophages from healthy donors did not. More...
The study was published in the October 2002 issue of Cancer Research.

"This research establishes that macrophages can cause disease as opposed to current dogma, which asserts that the purpose of these cells is benevolent, solely to assist in fighting disease,” said the study's lead investigator, Dr. Michael S. McGrath, professor of laboratory medicine at the University of California, San Francisco (USA; www.ucsf.edu).

The investigators injected SCID mice lacking functional T and B lymphocytes with tumor cells from HIV-infected patients with a rare form of non-Hodgkin's lymphoma. Some mice were injected with macrophages and lymphoma cells together, some with macrophages separately, and some with lymphoma cells separately. A control group of SCID mice was injected with macrophages from healthy subjects.

Tumors developed in the mice injected with both macrophages and lymphoma cells from the HIV-infected lymphoma patients and in the mice injected with only the macrophages from the HIV-infected lymphoma patients. No tumors were found in the mice injected with only the lymphoma T-cells from the HIV-infected lymphoma patients, and none of the mice injected with normal human macrophages from healthy subjects developed lymphomas.

Dr. McGrath explained, "Our theory is that, during HIV infection, disease associated macrophages have HIV inserted near growth-promoting genes allowing macrophages to become neoplastic and begin to proliferate. These proliferating macrophages (pro macs) do what all macrophages do and produce factors. Normal macrophages produce factors to help fight diseases. Pro macs, instead, produce factors that stimulate lymphoma growth.”




Related Links:
University of California, San Francisco

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.